Both Gamida Cell Ltd. (NASDAQ:GMDA) and InflaRx N.V. (NASDAQ:IFRX) are each other’s competitor in the Biotechnology industry. Thus the compare of their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Gamida Cell Ltd.||N/A||0.00||36.05M||-1.24||0.00|
We can see in table 1 the earnings per share, top-line revenue and valuation of Gamida Cell Ltd. and InflaRx N.V.
Table 2 has Gamida Cell Ltd. and InflaRx N.V.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Gamida Cell Ltd.||0.00%||0%||0%|
5.8 and 5.8 are the respective Current Ratio and a Quick Ratio of Gamida Cell Ltd. Its rival InflaRx N.V.’s Current and Quick Ratios are 18.7 and 18.7 respectively. InflaRx N.V. has a better chance of clearing its pay short and long-term debts than Gamida Cell Ltd.
Insider & Institutional Ownership
Gamida Cell Ltd. and InflaRx N.V. has shares owned by institutional investors as follows: 0% and 58.8%. Gamida Cell Ltd.’s share owned by insiders are 48.91%.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Gamida Cell Ltd.||-24.27%||21.94%||0%||0%||0%||38.27%|
For the past year Gamida Cell Ltd. was less bullish than InflaRx N.V.
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company’s lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase 3 clinical trials for use as a curative stem cell graft for patients in hematopoietic stem cell transplant. It is also developing NAM-NK, an innate immunotherapy of expanded natural killer cells, which is in Phase 1 clinical trials for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was founded in 2007 and is headquartered in Jena, Germany.